Abstract:Cancer metastasis, the spread of disease from a primary to a distal site through the circulatory or lymphatic systems, accounts for over 90% of all cancer related deaths. Despite significant progress in the field of cancer therapy in recent years, mortality rates remain dramatically higher for patients with metastatic disease versus those with local or regional disease. Although there is clearly an urgent need to develop drugs that inhibit cancer spread, the overwhelming majority of anticancer therapies that have been developed to date are designed to inhibit tumor growth but fail to address the key stages of the metastatic process: invasion, intravasation, circulation, extravasation, and colonization. There is growing interest in engineering targeted therapeutics, such as antibody drugs, that inhibit various steps in the metastatic cascade. We present an overview of antibody therapeutic approaches, both in the pipeline and in the clinic, that disrupt the essential mechanisms that underlie cancer metastasis. These therapies include classes of antibodies that indirectly target metastasis, including anti-integrin, anticadherin, and immune checkpoint blocking antibodies, as well as monoclonal and bispecific antibodies that are specifically designed to interrupt disease dissemination. Although few antimetastatic antibodies have achieved clinical success to date, there are many promising candidates in various stages of development, and novel targets and approaches are constantly emerging. Collectively, these efforts will enrich our understanding of the molecular drivers of metastasis, and the new strategies that arise promise to have a profound impact on the future of cancer therapeutic development. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

Targeted Biopharmaceuticals for Cancer Treatment

Cell-Specific Biomarkers And Targeted Biopharmaceuticals For Breast Cancer Treatment

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges

Molecular Targeted Therapy of Cancer: the Progress and Future Prospect

Innovative Drugs Promote Precision Cancer Therapy

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Targeting Tumor Suppressor Genes for Cancer Therapy

Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation

Molecular targeted therapy for anticancer treatment

Exploring treatment options in cancer: Tumor treatment strategies

Research advances of targeted therapy of cancer

Targeting Cancer Metastasis with Antibody Therapeutics

Small Molecule Inhibitors Targeting the Cancers

Clinical development of targeted and immune based anti-cancer therapies

Emerging new therapeutic antibody derivatives for cancer treatment

Cancer therapy with antibodies

Receptor-Targeted Cancer Therapy

Protein Nanotherapeutics as an Emerging Modality for Cancer Therapy

An overview of targeted cancer therapy

Translational medicine promising personalized therapy in oncology